Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Astrocyte networks span large swaths of brain
The networks are plastic, connect brain regions that aren’t connected by neurons and may enable long-distance communication between astrocytes, a new preprint shows.
Astrocyte networks span large swaths of brain
The networks are plastic, connect brain regions that aren’t connected by neurons and may enable long-distance communication between astrocytes, a new preprint shows.
New findings on Phelan-McDermid syndrome; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 1 September.
New findings on Phelan-McDermid syndrome; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 1 September.
From bench to bot: Why AI-powered writing may not deliver on its promise
Efficiency isn’t everything. The cognitive work of struggling with prose may be a crucial part of what drives scientific progress.
From bench to bot: Why AI-powered writing may not deliver on its promise
Efficiency isn’t everything. The cognitive work of struggling with prose may be a crucial part of what drives scientific progress.